These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Risk factors for coughing in dogs with naturally acquired myxomatous mitral valve disease. Ferasin L, Crews L, Biller DS, Lamb KE, Borgarelli M. J Vet Intern Med; 2013; 27(2):286-92. PubMed ID: 23398050 [Abstract] [Full Text] [Related]
25. Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure. Mizuno M, Yamano S, Chimura S, Hirakawa A, Takusagawa Y, Sawada T, Maetani S, Takahashi A, Mizuno T, Harada K, Shinoda A, Uchida S, Takeuchi J, Mizukoshi T, Endo M, Uechi M. J Vet Med Sci; 2017 Jan 20; 79(1):29-34. PubMed ID: 27644192 [Abstract] [Full Text] [Related]
26. Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study. Chetboul V, Lefebvre HP, Sampedrano CC, Gouni V, Saponaro V, Serres F, Concordet D, Nicolle AP, Pouchelon JL. J Vet Intern Med; 2007 Jan 20; 21(4):742-53. PubMed ID: 17708394 [Abstract] [Full Text] [Related]
28. Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease. Ouellet M, Bélanger MC, Difruscia R, Beauchamp G. J Vet Intern Med; 2009 Jan 20; 23(2):258-63. PubMed ID: 19143935 [Abstract] [Full Text] [Related]
30. Pimobendan and its use in treating canine congestive heart failure. Bowles D, Fry D. Compend Contin Educ Vet; 2011 Nov 20; 33(11):E1. PubMed ID: 22101450 [Abstract] [Full Text] [Related]
31. Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases. de Madron E, King JN, Strehlau G, White RV. Can Vet J; 2011 Nov 20; 52(11):1219-25. PubMed ID: 22547843 [Abstract] [Full Text] [Related]
33. Tissue Doppler and strain imaging in dogs with myxomatous mitral valve disease in different stages of congestive heart failure. Tidholm A, Ljungvall I, Höglund K, Westling AB, Häggström J. J Vet Intern Med; 2009 Nov 20; 23(6):1197-207. PubMed ID: 19909428 [Abstract] [Full Text] [Related]
34. Assessment of global and regional left ventricular volume and shape by real-time 3-dimensional echocardiography in dogs with myxomatous mitral valve disease. Ljungvall I, Höglund K, Carnabuci C, Tidholm A, Häggström J. J Vet Intern Med; 2011 Nov 20; 25(5):1036-43. PubMed ID: 21848946 [Abstract] [Full Text] [Related]
36. The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study. Klein S, Nolte I, Rumstedt K, Sehn M, Raue JF, Weiner F, Treese JS, Beyerbach M, Bach JP. BMC Vet Res; 2021 Sep 25; 17(1):310. PubMed ID: 34563187 [Abstract] [Full Text] [Related]
37. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease. Hezzell MJ, Block CL, Laughlin DS, Oyama MA. J Vet Intern Med; 2018 Sep 25; 32(5):1509-1516. PubMed ID: 30216549 [Abstract] [Full Text] [Related]
38. Tricuspid annular plane systolic excursion in dogs with myxomatous mitral valve disease with and without pulmonary hypertension. Poser H, Berlanda M, Monacolli M, Contiero B, Coltro A, Guglielmini C. J Vet Cardiol; 2017 Jun 25; 19(3):228-239. PubMed ID: 28579307 [Abstract] [Full Text] [Related]